中国P站

Hormone Therapy; Breast Cancer; Endocrine Therapy; Prostate Cancer; Endometrial Cancer; Ovarian Cancer; Resistance Mechanisms; Biomarkers; Clinical Guidelines; Adverse Events; Abemaciclib; Alpelisib

Introduction

This study demonstrated that adding abemaciclib, a CDK4/6 inhibitor, to standard adjuvant endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. The benefits were consistent across various subgroups, offering a new treatment option for this patient population[1].

Understanding how hormone receptor-positive metastatic breast cancer develops resistance to endocrine therapies is critical for effective treatment. This review details key mechanisms, including alterations in estrogen receptor signaling, activation of alternative pathways like PI3K/AKT/mTOR, and epigenetic modifications, guiding the development of novel therapeutic strategies to overcome resistance[2].

This ASCO guideline update provides contemporary recommendations for adjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. It covers critical aspects like optimal therapy duration, selection of agents, and management of menopausal symptoms, ensuring clinicians can provide evidence-based care tailored to individual patient risk and preference[3].

Metastatic castration-resistant prostate cancer presents significant therapeutic challenges. This review outlines the current understanding of the disease, including mechanisms of resistance to androgen deprivation therapy, and discusses available treatment options, highlighting the ongoing efforts to develop new agents that can overcome resistance and improve patient outcomes[4].

Hormone therapy plays an evolving role in the management of endometrial cancer, particularly for low-grade, early-stage, or recurrent disease. This review highlights recent advances in understanding hormone receptor expression, the efficacy of progestins, and the potential for novel targeted agents, providing insights into personalized treatment approaches[5].

This pivotal trial investigated alpelisib, a PI3K inhibitor, in combination with fulvestrant for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer. The findings demonstrated significantly improved progression-free survival, establishing alpelisib as a new standard of care for this specific genetic subtype[6].

Hormone therapy for ovarian cancer is gaining renewed interest, especially for recurrent or low-grade serous subtypes. This review explores the current landscape of endocrine agents, including aromatase inhibitors and selective estrogen receptor modulators, and discusses emerging targets and biomarkers that could help refine patient selection and improve treatment efficacy[7].

Deciding on the optimal duration of adjuvant endocrine therapy for early hormone receptor-positive breast cancer is a complex clinical question. This comprehensive review synthesizes data from various trials, addressing the balance between reducing recurrence risk and managing long-term side effects, and offering insights into individualized treatment planning[8].

This ASCO clinical practice guideline provides essential recommendations for managing common adverse events associated with endocrine therapy for breast cancer. It covers a range of side effects, including hot flashes, musculoskeletal pain, and sexual dysfunction, offering practical strategies to improve patient adherence and quality of life during long-term treatment[9].

Biomarkers are increasingly vital in guiding treatment decisions for hormone receptor-positive, HER2-negative breast cancer. This article reviews current and emerging biomarkers, such as gene expression profiles and liquid biopsy markers, for predicting prognosis and response to endocrine therapy, moving towards more personalized and effective treatment strategies[10].

Description

Significant advancements are continually redefining the treatment landscape for hormone receptor-positive breast cancer. A landmark study revealed that incorporating abemaciclib, a CDK4/6 inhibitor, into standard adjuvant endocrine therapy substantially improved invasive disease-free survival for patients diagnosed with hormone receptor-positive, HER2-negative, node-positive early breast cancer who were at high risk of recurrence. The benefits observed were notably consistent across various patient subgroups, establishing a robust new treatment option for this specific patient population[1]. Simultaneously, tackling the challenge of hormone receptor-positive metastatic breast cancer necessitates a deep understanding of how resistance to endocrine therapies develops. Comprehensive reviews detail key resistance mechanisms, including alterations in estrogen receptor signaling, the activation of alternative pathways such as PI3K/AKT/mTOR, and epigenetic modifications. These insights are crucial for guiding the development of novel therapeutic strategies designed to effectively overcome resistance and improve patient outcomes in advanced disease settings[2].

Clinical practice guidelines are essential for consistent, high-quality care, especially in dynamic fields like oncology. A recent ASCO guideline update provides updated recommendations for adjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. This encompasses critical considerations such as determining the optimal duration of therapy, the selection of appropriate endocrine agents, and effective strategies for managing associated menopausal symptoms. These guidelines ensure that clinicians can deliver evidence-based care precisely tailored to individual patient risk profiles and preferences[3]. Complementing these guidelines, the complex clinical question of the optimal duration for extended adjuvant endocrine therapy in early hormone receptor-positive breast cancer has been thoroughly reviewed. This comprehensive synthesis of data from multiple trials carefully assesses the delicate balance between minimizing recurrence risk and effectively managing long-term side effects, offering valuable insights for personalized treatment planning that prioritizes both efficacy and patient well-being[8].

The advent of targeted therapies continues to refine and personalize breast cancer treatment. A pivotal trial focused on alpelisib, a PI3K inhibitor, administered in combination with fulvestrant for patients afflicted with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer. The findings unequivocally demonstrated significantly improved progression-free survival, firmly establishing alpelisib as a new standard of care for patients with this specific genetic subtype, thereby offering a crucial therapeutic advancement[6]. Moving forward, biomarkers are increasingly indispensable for guiding treatment decisions in hormone receptor-positive, HER2-negative breast cancer. Recent articles review both current and emerging biomarkers, including advanced gene expression profiles and liquid biopsy markers, which are critical for accurately predicting prognosis and individual response to endocrine therapy. This ongoing research is propelling the field towards more highly personalized and ultimately more effective treatment strategies, ensuring therapies are precisely matched to patient biology[10].

The application of hormone therapy extends beyond breast cancer, demonstrating evolving roles in other hormone-sensitive malignancies. Metastatic castration-resistant prostate cancer, for example, represents a significant therapeutic challenge. Recent reviews outline the current understanding of this aggressive disease, detailing mechanisms of resistance to androgen deprivation therapy and thoroughly discussing available treatment options. These discussions highlight continuous efforts to develop innovative new agents capable of overcoming resistance and substantially improving patient outcomes[4]. Furthermore, hormone therapy is playing an increasingly vital role in the management of endometrial cancer, particularly for low-grade, early-stage, or recurrent disease. Recent reviews illuminate advances in understanding hormone receptor expression, the proven efficacy of progestins, and the exciting potential for novel targeted agents, collectively offering deeper insights into personalized treatment approaches for this gynecological cancer[5]. Similarly, hormone therapy for ovarian cancer is experiencing a renewed interest, especially for recurrent or low-grade serous subtypes. Comprehensive reviews explore the current landscape of endocrine agents, including aromatase inhibitors and selective estrogen receptor modulators, alongside discussions on emerging targets and biomarkers that promise to help refine patient selection and significantly enhance treatment efficacy[7].

Ensuring patient adherence and maintaining quality of life during long-term endocrine therapy for breast cancer is paramount, given the potential for adverse events. To address this, an ASCO clinical practice guideline provides essential recommendations for effectively managing common side effects associated with endocrine therapy. This comprehensive guide covers a range of adverse events, including prevalent issues like hot flashes, musculoskeletal pain, and sexual dysfunction. It offers practical, evidence-based strategies designed to improve patient adherence to therapy and significantly enhance their overall quality of life throughout the extensive treatment period, reinforcing the importance of supportive care alongside therapeutic efficacy[9].

Conclusion

Recent advancements in hormone therapy have significantly impacted the management of various hormone-sensitive cancers. For hormone receptor-positive breast cancer, the addition of abemaciclib has shown to improve invasive disease-free survival in high-risk early-stage patients, offering a new treatment avenue[1]. Understanding and overcoming resistance mechanisms to endocrine therapies, such as alterations in estrogen receptor signaling and activation of alternative pathways, remains a critical research focus in metastatic breast cancer[2]. Clinical guidelines, like those from ASCO, continually update recommendations for adjuvant endocrine therapy, covering optimal duration, agent selection, and managing menopausal symptoms to ensure evidence-based, personalized care[3]. Debates surrounding the optimal duration of adjuvant endocrine therapy highlight the need to balance recurrence risk reduction with long-term side effect management[8]. Targeted treatments are also making strides, with alpelisib demonstrating improved progression-free survival in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer, establishing a new standard of care[6]. The role of biomarkers, including gene expression profiles, is increasingly vital for predicting prognosis and treatment response, paving the way for more personalized strategies[10]. Beyond breast cancer, hormone therapy is gaining traction in endometrial cancer for various stages and recurrent disease, driven by improved understanding of hormone receptor expression and novel targeted agents[5]. Similarly, interest in hormone therapy for ovarian cancer is renewing, particularly for recurrent or low-grade serous subtypes, focusing on endocrine agents and emerging biomarkers[7]. Patient quality of life is addressed through guidelines for managing adverse events associated with endocrine therapy, providing practical strategies for side effects like hot flashes and musculoskeletal pain to improve adherence[9]. Significant research also addresses metastatic castration-resistant prostate cancer, focusing on resistance mechanisms and new agents to improve patient outcomes[4].

References

1. Stephen RDJ, Matthew G, Giuseppe C (2020) .N Engl J Med 383:2007-2017.

   , ,

2. Vasiliki PS, Amir B, Sanchit C (2022) .Cancer Treat Rev 107:102402.

   , ,

3. Harold JB, Deborah KM, Sara HT (2021) .J Clin Oncol 39:1400-1411.

   , ,

4. Andrew JA, Emmanuel SA, Evan YY (2020) .J Clin Oncol 38:1546-1554.

   , ,

5. Dan-Mei L, Wen-Bo L, Rong Z (2023) .Gynecol Oncol 172:100-108.

   , ,

6. Fabrice A, Dejan J, Stephen J (2019) .N Engl J Med 380:1929-1940.

   , ,

7. A. MG, M. MAN, S. AME (2022) .Gynecol Oncol 164:1-10.

   , ,

8. Martine JP, Giuseppe C, Peter EPDV (2021) .J Clin Oncol 39:1412-1425.

   , ,

9. Kala V, Deborah KM, Julie RG (2023) .J Clin Oncol 41:1912-1925.

   , ,

10. Aleix P, Hope SR, William MS (2022) .Clin Cancer Res 28:4377-4389.

    , ,